Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low‐grade glioma patients - report from the German SIOP‐LGG 2004 cohort by Kandels, Daniela et al.
C AN C E R T H E R A P Y AND P R E V E N T I O N
Loss of efficacy of subsequent nonsurgical therapy after
primary treatment failure in pediatric low-grade glioma
patients—Report from the German SIOP-LGG 2004 cohort
Daniela Kandels1 | Torsten Pietsch2 | Brigitte Bison3 |
Monika Warmuth-Metz3 | Ulrich-Wilhelm Thomale4 | Rolf-Dieter Kortmann5 |
Beate Timmermann6 | Pablo Hernáiz Driever7 | Olaf Witt8 | René Schmidt9† |
Astrid K. Gnekow1†
1Swabian Children's Cancer Center, Medical
Faculty, University of Augsburg, Augsburg,
Germany
2Institute of Neuropathology, DGNN Brain
Tumor Reference Center, University of Bonn,
Bonn, Germany
3Institute of Diagnostic and Interventional




Member of Freie Universitaet Berlin,
Humboldt-Universitaet zu Berlin, and Berlin
Institute of Health, Berlin, Germany
5Department of Radio-Oncology, University
Hospital Leipzig, Leipzig, Germany
6Department of Particle Therapy, University
Hospital Essen, West German Proton Therapy
Centre Essen (WPE), West German Cancer
Center (WTZ), German Cancer Consortium
(DKTK), Essen, Germany
7Department of Pediatric Oncology/
Hematology, Charité Universitaetsmedizin
Berlin, Corporate Member of Freie Universitaet
Berlin, Humboldt-Universitaet zu Berlin, and
Berlin Institute of Health, Berlin, Germany
8Hopp Children's Cancer Center Heidelberg
(KiTZ), German Cancer Research Center
(DKFZ), and Heidelberg University Hospital,
Heidelberg, Germany
9Institute of Biostatistics and Clinical Research,
University of Münster, Münster, Germany
Abstract
First-line treatment of pediatric low-grade glioma using surgery, radio- or chemother-
apy fails in a relevant proportion of patients. We analyzed efficacy of subsequent sur-
gical and nonsurgical therapies of the German cohort of the SIOP-LGG 2004 study
(2004-2012, 1558 registered patients; median age at diagnosis 7.6 years, median
observation time 9.2 years, overall survival 98%/96% at 5/10 years, 15% neurofibro-
matosis type 1 [NF1]). During follow-up, 1078/1558 patients remained observed
without (n = 217), with 1 (n = 707), 2 (n = 124) or 3 to 6 (n = 30) tumor volume reduc-
tions; 480/1558 had 1 (n = 332), 2 (n = 80), 3 or more (n = 68) nonsurgical treat-
ment-lines, accompanied by up to 4 tumor-reductive surgeries in 215/480; 265/480
patients never underwent any neurosurgical tumor volume reduction (163/265 optic
pathway glioma). Patients with progressing tumors after first-line adjuvant treatment
were at increased risk of suffering further progressions. Risk factors were young age
(<1 year) at start of treatment, tumor dissemination or progression within 18 months
after start of chemotherapy. Progression-free survival rates declined with subsequent
treatment-lines, yet remaining higher for patients with NF1. In non-NF1-associated
tumors, vinblastine monotherapy vs platinum-based chemotherapy was noticeably
less effective when used as second-line treatment. Yet, for the entire cohort, results
did not favor a certain sequence of specific treatment options. Rather, all can be
aligned as a portfolio of choices which need careful balancing of risks and benefits.
Future molecular data may predict long-term tumor biology.
Abbreviations: BBSFOP, Baby Brain protocol of the French Society of Pediatric Oncology; CI, confidence interval; CNS, central nervous system; EC, European community; EFS, event-free
survival; HR, hazard ratio; LGG, low-grade glioma; MRI, magnetic resonance imaging; NF1, neurofibromatosis type 1; OPG, optic pathway glioma; OS, overall survival; PA, pilocytic astrocytoma;
PFS, progression-free survival; PFS-1, progression-free survival after first-line nonsurgical therapy; PFS-2, progression-free survival after second-line nonsurgical therapy; PFS-3, progression-free
survival after third-line nonsurgical therapy; PFS-4, progression-free survival after fourth-line nonsurgical therapy; SML, supratentorial midline; WHO, World Health Organization.
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1 | INTRODUCTION
Pediatric low-grade gliomas (LGGs) are heterogeneous at a clinical, neu-
ropathological and molecular level. They occur at all ages and sites of the
central nervous system (CNS)1,2 with a low risk for malignant transforma-
tion.3,4 Comprehensive treatment strategies have been developed for
pediatric LGG integrating various therapeutic approaches.1,2,5-14
Whereas neurosurgical resection is considered the treatment of
choice, a relevant portion of tumors is not amenable to complete
resection. Tumors may grow and alternate with phases of proliferative
arrest. Unresectable tumors and residues pose a risk for nonsurgical
treatment upon clinical and/or radiological progression.
Current treatment strategies schedule chemotherapy as first-line
treatment for most, in particular for the younger patients,6,8,10,15 to
avoid radiation. Radiotherapy is used more often in older patients.12,13
Most nonsurgical treatment modalities have shown high initial
response rates exceeding 90%. Still, these fail in a relevant proportion
of patients. More than half of patients suffer from tumor progression
after first-line chemotherapy16,17 and up to 30 % following first-line
radiotherapy.12,13,18,19 Using a multistate model for analysis of our
study cohort, Goebel et al identified patients with multiple interven-
tions after 2 years of diagnosis at increased risk for a highly progres-
sive disease biology and death.20 Although radiotherapy is superior to
chemotherapy in terms of progression-free survival (PFS),12,13,21 con-
cerns regarding long-term sequelae3,18,19,22-25 limit its application as
an approach especially in the very young. Thus, we and others rec-
ommended front-line chemotherapy for all patients26 accepting more
and earlier tumor progressions. Salvage chemotherapy upon further
progression was shown to be effective.9,16,17,27
Most salvage treatments have been analyzed for response to therapy,
whereas long-term follow-up data are scarce.16,17,28 So far, a comprehen-
sive strategy for patients with repeatedly progressive or relapsing LGG has
yet to be defined. Despite repeated progressions, overall survival (OS) for
these patients remains acceptable2,25,29 and most patients reach adult-
hood. LGG is a life-long disease for patients whose tumor location or dis-
semination do not allow surgical resection.20 All therapeutic efforts have
to minimize long-term sequelae due to disease and therapy.
We report the largest population-based and prospectively registered
cohort with extended follow-up. We examined the effect of subsequent
surgeries and nonsurgical therapies for pediatric LGG of all histologies and
locations. We analyzed risk factors for repeatedly progressive disease.
2 | PATIENTS AND METHODS
2.1 | Eligibility
The prospective multinational/multicenter study SIOP-LGG 2004 reg-
istered patients with LGG of all CNS localizations from 2004 to 2012.
Follow-up included information up to 10 July 2019. Inclusion criteria
were age < 18 years at diagnosis and histologic diagnosis of LGG
according to the respective World Health Organization (WHO)-classi-
fication of CNS tumors without prior nonsurgical therapy. In defined
cases, radiological diagnosis was accepted.15 Central review for
pathology and radiology was recommended.
2.2 | Treatment strategy
At diagnosis, best safe resection of the primary tumor was rec-
ommended. Patients with complete resection were to be
observed, as well as patients following incomplete resection,
biopsy or radiological diagnosis, provided they did not suffer from
tumor-related, severe neurologic symptoms. Upon clinical or
radiological progression,15 nonsurgical treatment was indicated if
resection was deemed unfeasible. For patients <8 years and for all
patients with NF-associated LGG chemotherapy as first-line
What's new
For some patients with pediatric low-grade glioma, first-line
treatment isn't enough. Here, the authors evaluated the effec-
tiveness of various second-line strategies, including surgical
and non-surgical therapies, in a German cohort. Risk factors for
tumor progression included age under 1 year at diagnosis, early
treatment failure, and tumor dissemination. Over the entire
cohort, the results did not clearly support one specific treat-
ment strategy as the best choice, although platinum-based
therapy performed better than vinblastine in non-NF1 tumors.
This is the first long term analysis of comprehensive treatment
strategies in recurrent tumors in a population-based, prospec-
tively registered pediatric low-grade glioma cohort.
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treatment was recommended, whereas older children could
receive primary radiotherapy instead15 (Figure S1).
2.3 | Treatment modalities
For this report, surgical interventions were divided into “therapeu-
tic” surgery, if relevant tumor volume reduction was achieved (ie,
partial, subtotal and complete resection), and “diagnostic” surgery
for biopsies. Extent of resection was confirmed by early postopera-
tive scanning (obtained within the first 48 hours after surgery, up
to 72 hours in exceptional circumstances) and combined surgical
and radiological judgement.26 Additional surgery for regulation of
increased cranial pressure (ie, ventriculostomy, external cerebrospi-
nal fluid drainage or ventricular-peritoneal shunting) was not con-
sidered for analysis.
First-line chemotherapy consisted of vincristine and carboplatin
given for 18 months. Additional etoposide was given during the induc-
tion period to patients allocated into the interventional arm of the
randomized study.15
Focal radiotherapy by either photon or proton external beam
radiation was applied with a total dose of 54 Gy (1.8 Gy per fraction),
whereas individual concepts were used in case of craniospinal radia-
tion for disseminated disease. Brachytherapy/interstitial radiotherapy
for suitable tumors was applied with 125-iodine seeds, but restricted
to small and circumscribed tumors of selected sites.
Treatment for progression following primary radio- or chemother-
apy was not standardized, but included all modalities, including publi-
shed and individualized regimens (Table S1), following discussion in
local and reference tumor boards.
Nonsurgical treatment modalities (chemotherapy and radiother-
apy) are referred to as “adjuvant” treatment. Patients receiving
everolimus for subependymal giant cell astrocytoma associated with
tuberous sclerosis were allocated to the observation group.
2.4 | Neuroimaging
Radiologic diagnosis was accepted, if the tumor was not amenable
to surgery, for hypothalamic-chiasmatic tumors associated with
neurofibromatosis type 1 (NF1), or for tumors extending along
visual pathways and demonstrating hypodensity on a native com-
puted tomography scan. Contrast-enhanced magnetic resonance
imaging (MRI) was performed at defined intervals in all patients and
was planned at Week 24, 54 and 85 after the start of nonsurgical
therapy for response assessment. Definitions for radiological
response followed published consensus.26,30-32
2.5 | Statistics
For continuous variables, median and range are given. Categorical var-
iables are indicated in absolute or relative frequencies.
The distribution of survival times was estimated with the Kaplan-
Meier method and compared between independent groups using log-
rank test. OS was calculated from date of diagnosis until death of any
cause. Event-free survival (EFS) was calculated from date of diagnosis
until event, defined as relapse after complete resection, clinical or
radiological progression, start of nonsurgical/adjuvant therapy or
death of any cause. Patients without event were censored at the date
of last MRI. To evaluate the variable “extent of resection,” EFS and
OS were in derogation thereof calculated from the date of surgery
until event.
Progression-free survival after first-line therapy (PFS-1) was cal-
culated from the start of first nonsurgical/adjuvant therapy until
event, defined as relapse after complete remission, clinical or radiolog-
ical progression or death of any cause. Analogously, progression-free
survival after second-line (PFS-2), third-line (PFS-3) and fourth-line
therapy (PFS-4) was calculated from the start of second, third and
fourth nonsurgical/adjuvant therapy until event, respectively.
Radiation-free survival (RFS) was calculated from the start of first
chemotherapy until start of first radiotherapy or death of any cause.
Cox regression with forward stepwise selection (inclusion crite-
rion: score test P ≤ .05; exclusion criterion: likelihood ratio test
P > .10) was used to analyze the prognostic value of clinical and bio-
logic variables on PFS-1 and PFS-2. Multivariable analysis of PFS after
first-line/second-line chemotherapy or radiotherapy included all vari-
ables indicated in Table 3 and 4, respectively. For the final multivari-
able models, hazard ratios (HRs) of selected variables with their 95%
confidence intervals (CIs) and likelihood ratio P values are shown.
Kaplan-Meier estimates for PFS-1, PFS-2, PFS-3 and PFS-4 were
based on a common set of patients and thus stochastically dependent.
Accordingly, statistical tests to compare PFS-1, PFS-2, PFS-3 and
PFS-4 rates were calculated while adjusting for the worst-case depen-
dence structure (adjusted P values).
Analyses were exploratory, and P values were considered as
descriptive measures to detect and study meaningful effects. In partic-
ular, no significance level was fixed.
3 | RESULTS
3.1 | Epidemiologic data
From 2004 to 2012, 1586 previously untreated children and adoles-
cents with LGG from 81 German centers were registered. Twenty-
eight patients were excluded for inconsistent diagnosis, missing data,
displaying WHO-grade II H3.3K27M mutation upon molecular-
genetic testing,33 receiving first-line nonsurgical therapy without
specified15 or nonprotocol first-line chemotherapy (Figure 1). Thus,
analysis is based on 1558 patients; epidemiological data are given in
Table 1. Median age at diagnosis was 7.6 years. No age peak was
noted for non-NF1 patients, whereas two thirds of the NF1 patients
(62%) were aged 1 to 5 years at diagnosis (Figure S2).
Tumor location differed with NF status: In non-NF1 patients,
most tumors (34%) were located in the cerebellum, followed by the

















F IGURE 1 Course of disease and treatment cascade with patient numbers throughout the lines of therapy. “Surgery” comprises relevant
tumor reduction in terms of complete, subtotal or partial resection, but neither biopsies nor interventions for regulation of increased cranial
pressure
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supratentorial midline (SML) (28%) and cerebral hemispheres (27%),
while 87% of NF1-associated tumors evolved from the SML and
affected the optic pathways in 78%.
Dissemination was detected in 75 patients (5%). Infants diag-
nosed within the first year of life were more likely to develop dissemi-
nation (17%) when compared to patients aged 1 to <8 years or
≥8 years (5% or 4%, respectively). Although dissemination was pre-
sent in 13/36 infants with chiasmatic-hypothalamic LGG, it was seen
in none of 39 infants with tumors in in other CNS regions (Figure S3).
Just one NF1 patient developed secondary dissemination.
Histological diagnosis of a LGG was confirmed in 1245 patients
(centrally reviewed: 1136), whereas 20 patients had inconclusive his-
tological results and 293 were diagnosed upon radiological criteria
only (173/293 NF1).
Progression to high-grade histology evolved in 26/1558 patients
(2 NF1) after up to 14 years from first diagnosis, resulting in a 10-
years malignant transformation rate measured from diagnosis of 1.8%.
Malignant transformation occurred more often in spinal (4/54), caudal
brainstem (4/117) and hemispheric tumors (11/359), but in none of
460 cerebellar tumors. Initial histologic diagnosis had been pilocytic
astrocytoma WHO-grade I (PA) in 9, diffuse glioma WHO-grade II in
11 and ganglioglioma WHO-grade I in 4. Two patients with optic
pathway glioma (1 NF1) underwent first tumor-related surgery for
progression 6.1 and 14.0 years after radiological diagnosis, revealing
high-grade histology. After malignant transformation, all patients
followed high-grade glioma protocols and were censored for further
analysis.
3.2 | Outcome data
3.2.1 | OS and current status
Median observation time was 9.2 years. OS was 98% at 5 years and
96% at 10 years; 55 patients died after median 3.9 years, one as late
as 17.9 years from initial diagnosis. Survival was inferior for patients
aged <1 year at diagnosis, with disseminated tumor, with tumor loca-
tion in the caudal brainstem and spinal cord, and for patients without
therapeutic surgery. Patients with early events within 18 months from
start of first-line chemotherapy had a distinctly increased mortality
(Table 2). At last follow-up, 1503/1558 patients were alive; median
observation time for surviving patients was 9.3 years; median age at
last contact was 17.6 years.
3.2.2 | Surgical and nonsurgical treatment from
diagnosis
Until last follow-up, 1078 patients remained observed without initia-
tion of nonsurgical treatment. Of these, 217 never underwent thera-
peutic surgery, whereas 707 and 124 had 1 or 2 surgeries,
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All 1558 98.1 (0.4) 96.3 (0.5) — 1558 54.1 (1.3) —
Sex .921 .259
Male 831 98.1 (0.5) 96.1 (0.7) 831 55.4 (1.8)
Female 724 98.1 (0.5) 96.5 (0.7) 724 52.7 (1.9)
Age at diagnosis .001 <.001
<1 y 75 90.7 (3.4) 87.7 (3.9) 75 22.5 (5.0)
≥1 to <8 y 735 98.2 (0.5) 96.7 (0.7) 735 48.8 (1.9)
≥8 y 748 98.6 (0.4) 96.8 (0.7) 748 62.6 (1.8)
Neurofibromatosis statusa .510 <.001
Non-NF1 1329 97.8 (0.4) 96.1 (0.6) 1329 57.4 (1.4)
NF1 228 99.6 (0.4) 98.0 (1.0) 228 35.1 (3.2)
Tumor locationb <.001 <.001
Cerebral hemispheresc 359 99.4 (0.4) 97.6 (1.0) 359 67.5 (2.6)
Optic pathways 330 96.7 (1.0) 93.8 (1.4) 330 26.8 (2.5)
SML outside the optic pathwaysd 237 96.6 (1.2) 94.8 (1.5) 237 44.4 (3.3)
Cerebellum 460 99.8 (0.2) 99.8 (0.2) 460 74.2 (2.1)
Caudal brainstem 117 96.6 (1.7) 91.7 (2.9) 117 39.3 (4.6)
Spinal cord 54 92.6 (3.6) 92.6 (3.6) 54 38.5 (6.7)
Dissemination status <.001 <.001
No dissemination 1483 98.6 (0.3) 97.4 (0.5) 1483 56.5 (1.3)
Dissemination 75 86.7 (3.9) 75.6 (5.3) 75 8.0 (3.1)
Histologye .033 .031
PA WHO grade If 841 98.4 (0.4) 96.3 (0.7) 841 54.1 (1.7)
Diffuse glioma WHO grade II 102 93.0 (2.5) 88.8 (3.4) 102 44.8 (5.1)
PXA WHO grade II 14 100 (0.0) 100 (0.0) 14 50.0 (13.4)
DNT WHO grade I 48 97.9 (2.1) 97.9 (2.1) 48 69.5 (6.8)
Ganglioglioma WHO grade I 143 99.3 (0.7) 98.1 (1.4) 143 66.2 (4.0)
Other 97 94.7 (2.3) 93.5 (2.6) 97 56.5 (5.3)
Extent of first surgeryg,h <.001 <.001
Complete resection 518 99.4 (0.3) 98.4 (0.7) 496 83.6 (1.7)
Subtotal resection 137 100 100 134 64.5 (4.2)
Partial resection 353 97.1 (0.9) 93.5 (1.5) 335 44.1 (2.8)
Biopsy 255 94.4 (1.5) 91.2 (1.8) 183 29.1 (3.4)
Time to event after primary radiotherapyi .682 —
Event ≤18 mo. after start of therapy 20 70.0 (10.2) 70.0 (10.2) —
Event >18 mo. after start of therapy 15 78.8 (11.0) 78.8 (11.0) —
Time to event after primary chemotherapyi <.001 —
Event ≤18 mo. after start of therapy 55 65.4 (6.5) 52.9 (7.4) —
Event >18 mo. after start of therapy 121 94.3 (2.3) 92.2 (3.1) —
Abbreviations: DNT, dysembryoplastic neuroepithelial tumor; NF1, neurofibromatosis type 1; PA, pilocytic astrocytoma; PXA, pleomorphic
xanthoastrocytoma; SML, supratentorial midline.
aExcluded: one male patient with neurofibromatosis type 2, radiological diagnosis of optic pathway glioma at the age of 12 years; he died of another tumor
without nonsurgical therapy for his optic pathway glioma.
bExcluded: one patient whose primary tumor was not assessable.
cIncluding tumors of the lateral ventricles.
dIncluding thalamus, hypothalamus, basal ganglia, corpus callosum and mesencephalon.
eExcluded: 313 patients without histological diagnosis.
fIncluding: 19 patients with pilomyxoid astrocytoma.
gExcluded for OS: two patients with extent of surgery not assessable; OS calculated from date of surgery.
hExcluded for EFS: 115 patients with event prior to surgery, two patients with extent of surgery not assessable; EFS calculated from date of surgery.
iIncluding patients with event after start of nonsurgical therapy; OS calculated from date of event.
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Allb 307 65.7 (2.7) 53.2 (2.9) — 96 28.1 (4.8) —
Sex .449 .573
Male 157 63.7 (3.8) 55.9 (4.0) 51 31.5 (6.7)
Female 150 67.7 (3.8) 50.5 (4.1) 45 24.0 (7.0)
Neurofibromatosis status <.001 .007
Non-NF1 181 53.5 (3.7) 39.9 (3.7) 66 23.0 (5.3)
NF1 126 83.2 (3.3) 72.4 (4.0) 30 40.3 (10.2)
Age at diagnosis <.001 .290
<1 y 37 37.8 (8.0) 24.3 (7.1) 25 18.8 (8.3)
≥1 to <8 y 228 71.0 (3.0) 58.5 (3.3) 54 30.9 (6.7)
≥8 y 42 61.2 (7.6) 50.8 (7.9) 17 33.1 (11.8)
Age at start of first-line therapy <.001 .114
<1 y 29 24.1 (7.9) 10.3 (5.7) 22 18.2 (8.2)
≥1 to <8 y 206 70.9 (3.2) 58.1 (3.4) 53 31.1 (6.9)
≥8 y 72 67.7 (5.6) 57.2 (5.9) 21 31.7 (10.4)
Tumor locationc .433 .083
Cerebral hemispheres 11 72.7 (13.4) 54.5 (15.0) 1 0 eventsd
Optic pathways 188 66.8 (3.4) 53.1 (3.7) 65 27.4 (5.9)
SML outside the optic pathwayse 46 63.0 (7.1) 54.0 (7.4) 14 42.9 (13.2)
Cerebellum 11 81.8 (11.6) 81.8 (11.6) 2 1 eventd
Caudal brainstem 40 57.4 (7.8) 44.3 (7.9) 10 0.0
Spinal cord 10 60.0 (15.5) 60.0 (15.5) 3 2 eventsd
Dissemination status <.001 .067
No dissemination 261 72.3 (2.8) 60.4 (3.1) 65 30.6 (6.2)
Dissemination 46 28.3 (6.6) 12.2 (5.0) 31 22.6 (7.5)
Histologyf .698 .469
PA WHO-grade Ig 151 50.7 (4.1) 36.9 (4.0) 60 21.8 (5.5)
Diffuse glioma WHO-grade II 14 50.0 (13.4) 35.7 (12.8) 6 0.0
Ganglioglioma WHO-grade Ih 7 57.1 (18.7) 28.6 (17.1) 7 28.6 (17.1)
Otherh 15 60.0 (12.6) 53.3 (12.9)
Extent of maximum surgery before
start of first-line chemotherapy
<.001 —
Complete resection 6 83.3 (15.2) 83.3 (15.2) —
Subtotal resection 13 76.9 (11.7) 76.9 (11.7) —
Partial resection 75 60.0 (5.7) 42.3 (5.7) —
Biopsy 65 47.2 (6.2) 37.4 (6.1) —
None 148 74.9 (3.6) 62.4 (4.0) —
Time from diagnosis to first treatment <.001 .560
<3 mo. 133 49.2 (4.4) 36.6 (4.2) 57 24.0 (5.9)
3 to <12 mo. 74 78.4 (4.8) 70.3 (5.3) 16 16.7 (9.9)
12 to <24 mo. 33 72.7 (7.8) 57.4 (8.6) 9 50.0 (17.7)
2 to <5 yi 46 82.5 (5.6) 64.2 (7.2) 14 47.6 (14.0)
≥5 yi 21 76.2 (9.3) 66.7 (10.3)
(Continues)
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A total of 480 patients had at least one nonsurgical therapy (261
after prior radiologic progression). Of these, 332 patients received 1,
80 patients 2 and 68 patients 3 or more nonsurgical treatment lines
(Figure 1).
Prior to first adjuvant treatment, 170/480 patients had 1 to 4
therapeutic surgeries, while in 45/480 patients without up-front
tumor reduction, it was eventually performed after 1 to 4 nonsurgical
therapies. Still, 265/480 patients never had any surgical tumor volume
reduction (226/265 SML, 163 of these in the optic pathways). Modes
of applied treatments and indications for first nonsurgical therapy are
displayed in Tables S1 and S2.
Most of the total of 1382 therapeutic surgeries was performed
for tumors in the cerebral hemispheres (391/1382; 28%) and cerebel-
lum (552/1382; 40%). At times, complete resection required repeated
interventions and was achieved in 579 patients; the majority had
tumors in the cerebral hemispheres (206/579; 36%) or cerebellum
(314/579; 54%).
Within the observation time, a total of 730 nonsurgical therapies
were applied. The majority was given to patients with optic pathway
glioma (OPG; 394/730; 54%), with tumors in the SML outside the
optic pathways (ie, thalamus, hypothalamus, basal ganglia, corpus cal-
losum, mesencephalon; 143/730; 20%) or the caudal brainstem (87/
730; 12%) (Table S3).
3.2.3 | Event-free survival
With a median follow-up of 8.3 years to last neuroimaging, EFS was 54%
at 5 years and 49% at 10 years for the entire cohort (range: 0.0-
13.4 years). EFS was lower in patients aged <1 year, with OPG, with dis-
semination and with a lesser extent of first resection (Table 2). At last fol-
low-up, 809/1558 patients were alive without event after complete
(n = 422), subtotal (n = 80) or partial (n = 123) tumor resection, or with-
out therapeutic surgery (n = 182; extent or resection unknown: n = 2).
3.2.4 | Treatment following first event
During follow-up, 749/1558 patients experienced an event, which
was start of first nonsurgical therapy in 219 (14%) and radiological
progression/relapse in 508 (33%), associated with malignant transfor-
mation in another 11 (1%) and 11 patients (1%) died (tumor progres-
sion: 2, diencephalic dysfunction after complete tumor resection: 2,
major seizure: 1, sepsis: 2, malignant peripheral nerve sheath tumor: 1,
unknown reason: 3).
Progression/relapse occurred up to 13.4 years from diagnosis and
was seen in 80/508 patients after initial complete resection, in 225














Type of second-line chemotherapy .291
Platinum-based combinationsj 56 24.1 (5.8)
Vinblastine mono 28 27.7 (9.6)
All others 12 53.0 (15.5)
Type of second-line chemotherapy with respect to NF status .005
Platinum-based combinationsj Non-NF1 patients 46 23.9 (6.3)
NF1 patients 10 18.0 (15.1)
Vinblastine mono Non-NF1 patients 12 8.3 (8.0)
NF1 patients 16 47.9 (14.4)
All others Non-NF1 patients 8 50.0 (17.7)
NF1 patients 4 66.7 (27.2)
Abbreviations: n.a., not applicable; NF1, neurofibromatosis type 1; PA, pilocytic astrocytoma; SML, supratentorial midline.
aFirst-line chemo- or radiotherapy.
bExcluded for missing follow-up data following the start of therapy: one patient for PFS-1, three patients for PFS-2.
cExcluded: one patient whose primary tumor was not assessable.
dNot included in analysis due to small group size; the number of events up to Year 3 is indicated.
eIncluding thalamus, hypothalamus, basal ganglia, corpus callosum and mesencephalon.
fExcluded: 120 patients without histological diagnosis (PFS-1), 23 patients (PFS-2).
gIncluded: 14 patients with pilomyxoid astrocytoma (PFS-1), nine patients (PFS-2).
hPooled for analysis of PFS-2: three patients with ganglioglioma WHO-grade I and four patients with other histologies.
iPooled for analysis of PFS-2: all patients with time since diagnosis to first treatment ≥2 years.
jIncluding: vincristine/carboplatin ± etoposide; vincristine/cyclophosphamide/cisplatin.
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Allb 171 80.1 (3.2) — 46 48.7 (7.7) —
Sex .923 .097
Male 91 78.8 (4.5) 20 36.9 (11.3)
Female 80 81.6 (4.5) 26 58.1 (10.2)
Neurofibromatosis status .978 .056
Non-NF1 162 79.6 (3.3) 41 52.4 (8.2)
NF1 9 88.9 (10.5) 5 20.0 (17.9)
Age at diagnosis .038 .882
<1 y 5 30.0 (23.9) 2 2 eventsc
≥1 to <8 y 56 85.3 (4.8) 36 49.9 (8.6)
≥8 y 110 79.6 (4.0) 8 60.0 (18.2)
Age at start of first non-surgical therapy .686 .463
<1 y 2 2 eventsc 2 2 eventsc
≥1 to <8 y 29 86.2 (6.4) 32 53.1 (9.2)
≥8 y 140 80.2 (3.5) 12 46.9 (15.0)
Tumor location .200 .913
Cerebral hemispheres 19 68.4 (10.7) 3 1 eventc
Optic pathways 45 77.3 (6.3) 20 47.8 (11.5)
SML outside the optic pathwaysd 57 81.2 (5.4) 12 38.7 (16.3)
Cerebellum 21 95.0 (4.9) 2 1 eventc
Caudal brainstem 18 82.4 (9.2) 7 57.1 (18.7)
Spinal cord 11 75.0 (15.8) 2 1 eventc
Dissemination status <.001 .004
No dissemination 156 83.3 (3.0) 38 53.9 (8.6)
Dissemination 15 36.2 (15.4) 8 25.0 (15.3)
Histologye .001 .371
PA WHO grade If 109 82.4 (3.8) 28 44.2 (9.7)
Diffuse glioma WHO grade II 19 77.8 (9.8) 7 50.0 (20.4)
Ganglioglioma WHO grade Ig 14 46.2 (13.8) 7 33.3 (19.2)
Otherg 10 77.8 (13.9)
Extent of maximum surgery before start of first-line radiotherapy .941 —
Complete resection 13 76.2 (12.1) —
Subtotal resection 10 80.0 (12.6) —
Partial resection 52 79.2 (5.9) —
Biopsy 56 83.0 (5.2) —
None 40 78.6 (6.7) —
Time from diagnosis to first treatment .960 .009
<3 mo. 49 80.7 (5.8) 24 61.4 (10.2)
3 to <12 mo. 34 81.3 (6.9) 10 53.3 (17.6)
12 to <24 mo.h 19 78.9 (9.4) 12 18.5 (11.8)
2 to <5 yh 42 81.6 (6.3)
≥5 yh 27 77.0 (8.3)
Mode of radiotherapy .516 —
Interstitial radiosurgery (brachytherapy) 59 83.9 (4.9) —
(Continues)
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tic surgery (62 with biopsy). Following progression/relapse, 139/508
patients had further debulking and 105 remained observed only,
whereas 261 patients received first-line nonsurgical therapy; for three
patients no information was available (Figure 1).
Thus, nonsurgical treatment was given to 480/1558 patients defined
as first event for 219 patients and following progression/relapse in 261.
3.2.5 | Progression-free survival after first
nonsurgical therapy (PFS-1)
With a median follow-up of 8.5 years (range: 0.0-14.6 years) from
start of therapy to last neuroimaging, 5-years PFS-1 was 53% after
first-line chemotherapy and 80% after first-line radiotherapy. PFS-1
following chemotherapy was noticeably higher for NF1-associated
tumors. It was lower for patients with dissemination and for patients
who started treatment within the first year of life. For patients with
chemotherapy, 5-years-PFS-1 was lower for those with lesser extent
of resection and for those who started therapy within 3 months after
diagnosis, whereas PFS-1 after primary radiotherapy was neither
associated with the extent of prior resection nor with the interval
between diagnosis and start of treatment. PFS-1 after primary radio-
therapy did not differ with respect to radiation mode (Tables 3 and 4).
Multivariable analysis confirmed four prognostic factors for an
event: (a) following first-line chemotherapy: non-NF1 status, start of












Photon-beam therapy, focal 93 81.9 (4.1) —
Proton-beam therapy, focal 15 70.6 (12.6) —
Abbreviations: NF1, neurofibromatosis type 1; PA, pilocytic astrocytoma; SML, supratentorial midline.
aAfter first-line chemotherapy.
bExcluded for missing follow-up data following the start of therapy: one patient for PFS-1, three patients for PFS-2.
cNot included in analysis due to small group size; only the number of events up to Year 5 is indicated.
dIncluding thamalus, hypothalamus, basal ganglia, corpus callosum, mesencephalon.
eExcluded: 19 patients without histological diagnosis (PFS-1), four patients (PFS-2).
fIncluded: three patients with pilomyxoid astrocytoma (PFS-1), one patient with pilomyxoid astrocytoma (PFS-2).
gPooled for analysis of PFS-2: four patients with ganglioglioma WHO-grade I and three patients with other histologies.
hPooled for analysis of PFS-2: all patients with time since diagnosis to first treatment ≥12 months.
(A) (B)





F IGURE 2 PFS after second-line chemotherapy. A, For platinum-based* vs VBL monotherapy; B, for platinum-based* vs VBL monotherapy
and for NF1 status. * including: vincristine/carboplatin ± etoposide and vincristine/cyclophosphamide/cisplatin; results for other regimen are not
shown due to small group size. NF1, neurofibromatosis type 1; PFS, progression-free survival; VBL, vinblastine





P < .001 P < .001
P = .017 P = .008
P = .001 P = 1.000
P = 1.000 P < .001
F IGURE 3 PFS for first-line and
rescue (second-line, third-line and forth-
line) therapies. A, PFS for radiation
(irrespective of the modality of previous
treatments); B, PFS for chemotherapy
(irrespective of the modality of previous
treatments); C, PFS for chemotherapy for
non-NF1 patients; D, PFS for
chemotherapy for NF1 patients; E, PFS
for chemotherapy for patients without
tumor dissemination; F, PFS for
chemotherapy for patients with
disseminated tumor; G, PFS for
chemotherapy for patients aged < 1 year
at start of first treatment; H, PFS for
chemotherapy for patients aged ≥ 1 year
at start of first treatment. NF1,
neurofibromatosis type 1; PFS,
progression-free survival
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(P < .001; HR 2.95; CI 2.02-4.30, vs no dissemination); (b) following
first-line radiotherapy: ganglioglioma (P = .010; HR 4.20; CI 1.81-9.75,
vs PA) (Table S4).
3.2.6 | Treatment following first nonsurgical
therapy
Following first nonsurgical therapy, 262/480 patients stayed
observed without further event. Tumor progression occurred in
194 patients at an interval of up to 14.1 years, associated with
malignant transformation in another six. Seven patients were cen-
sored for further analysis as second-line treatment was started
without radiological or clinical progression. Eleven patients died
(primary tumor: 4, sepsis: 2, other malignant neoplasia associated
with NF1: 3, unknown reason: 2).
Following progression, 22/194 had further tumor surgery and
18 remained observed with spontaneous tumor stabilization,
whereas 148 patients received second-line nonsurgical therapy; for
six patients no information was available (Figure 1). Median time
from progression to start of second-line therapy was 0.17 years
(range: 0.0-6.8 years).
3.2.7 | Progression-free survival after second
nonsurgical therapy (PFS-2)
With a median follow-up of 5.7 years (range: 0.0-13.1 years) from
start of second therapy to last neuroimaging, PFS-2 was 28% at
3 years for all patients receiving second-line chemotherapy and
49% at 5 years for patients receiving radiation as second-line
treatment.
After second-line chemotherapy, 3-years PFS-2 differed with
respect to NF1 status (Table 3). No relevant differences in PFS-2 were
seen with respect to age at diagnosis, age at start of first treatment,
dissemination or time from diagnosis to first nonsurgical treatment.
The mode of pretreatment did not affect PFS-2 after second-line che-
motherapy, being 33% or 27% at 3 years after first-line-radiotherapy
or first-line chemotherapy, respectively.
The choice of the chemotherapeutic regimen for second-line
treatment did not influence PFS-2, if the cohort was analyzed in its
entirety. Yet, 3-years PFS-2 after therapy with vinblastine reached
48% for patients with NF1, but dropped to 8% for non-NF1
patients (Table 3, Figure 2A,B). Multivariable analysis confirmed a
noticeably higher risk for progression following vinblastine mon-
otherapy salvage approach in non-NF1 patients when compared to
vincristine/carboplatin or vincristine/cisplatin/cyclophosphamide
treatment (P = .003; HR 2.80; CI 1.43-5.50) (Table S4).
After second-line radiotherapy, 5-years PFS-2 reached 49% for
all. It was lower for patients with disseminated tumors, but did not
show differences with respect to tumor location or histology
(Table 4).
3.2.8 | Subsequent treatment following second
nonsurgical therapy
Following second nonsurgical therapy, 47/148 patients stayed
observed without further event. Tumor progression was diagnosed in
86 patients at an interval of up to 8.1 years, associated with malignant
transformation in another five. Two patients were censored for fur-
ther analysis as third-line therapy was started without radiological or
clinical progression. Eight patients died (primary tumor: 6, seizures: 1,
unknown reason: 1).
Following tumor progression, 10/86 patients underwent thera-
peutic tumor surgery, whereas seven remained observed with sponta-
neous tumor stabilization (in 1/7 patient the tumor progressed again
after a 10-years interval); for one patient, no information was avail-
able. In 68 patients, third-line adjuvant treatment was started. Median
time from progression to start of third-line therapy was 0.1 years
(range: 0.0-3.5 years).
3.2.9 | Progression-free survival after first (PFS-1),
second (PFS-2), third (PFS-3) or further rescue
treatments for sequence of treatments
PFS changed with progressing treatments (Figure 3A-H): Three-years
PFS was 66% after first-line chemotherapy (PFS-1), but dropped to
28% after second-line chemotherapy (PFS-2). Subsequent chemother-
apies reached a PFS in the same range. This pattern was modified
slightly by the modality of previous treatments (ie, radiation or chemo-
therapy). Three-years PFS-3 was 30% for all patients with third-line
chemotherapy, but was lower for patients being pretreated with two
chemotherapies (26%) in contrast to patients who had received radio-
therapy as part of their prior treatments (42%) (Table S5). A similar
trend was seen in patients with NF1-associated tumors after multiple
rescue chemotherapies, but at a higher level for all PFS-curves: PFS-1
was higher compared to PFS after rescue therapies, which were quite
parallel for second- and third-line chemotherapy ranging from 39% to
47% (Table S5). Of note, for patients with tumor dissemination or
age < 1 year at start of first treatment, PFS-1 was already as low as
PFS-2 and PFS-3. Small sample size precluded further analysis of a
possible impact of histology or tumor location.
Five-years PFS was 80% after first-line radiotherapy (PFS-1) and
dropped to 49% for second-line radiotherapy after prior chemother-
apy (PFS-2), but did not decrease further after two or more prior che-
motherapies (Table S6). Further subgroup analyses for rescue
radiotherapy could not be performed due to small patient numbers.
4 | DISCUSSION
This report presents the first population-based, prospectively regis-
tered pediatric LGG cohort which allowed long-term analysis of the
course of disease focusing upon repeatedly progressing tumors within
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a comprehensive treatment strategy. The sequence of surgical and
nonsurgical therapies in our cohort mirrored tumor location with
emphasis of surgical therapy for cerebral hemispheric and cerebellar
LGG, whereas SML tumors including OPG were predominantly
treated nonsurgically.
4.1 | Initial management
Our cohort was comparable to previously published series with
respect to age distribution, sex and portion of NF1 as well as distribu-
tion of tumor sites and the various low-grade histologies and 10-years
OS above 95%.1,2,14,29
Corroborating previous series, the extent of tumor removal
impacted strikingly upon overall and EFS. Progression was less fre-
quent in cerebellar and hemispheric sites than in LGG of the SML,
caudal brainstem or spinal cord where limited surgical approaches
resulted in mostly incompletely resected LGG.1,14,34-36 Yet, relapse in
our cohort was observed in one out of six patients even after com-
plete resection, implying an invasive growth pattern on the micro-
scopic level even in LGG.37,38 Though there was a trend for more
frequent progressions/relapses in pediatric LGG WHO-grade II and
less in glioneuronal tumors, the impact of histology has to be related
to its frequency at certain tumor sites.1,14,29 Nonetheless, the majority
of our patients (69%) with LGG at all CNS sites remained observed
without need of nonsurgical treatment following diagnosis with or
without any tumor-related therapeutic surgery.
Radiologic tumor progression or severe or progressive neuro-
logic, ophthalmologic or clinical symptoms prompted nonsurgical
treatment in 31% of all patients corresponding to the fraction
reported in previous population-based1,2 or large institutional29,34
cohorts. Of note, more than a third of patients receiving adjuvant
therapy had up to four prior attempts of surgical tumor removal,
whereas resection during the further course was attempted in less
than 10%. Nevertheless, in the course of the cascade of treatment
lines, growth arrest was reached for a third of patients at each
stage. Even tumors with intermittent progressions did not always
prompt further intervention but stabilized spontaneously in some
patients.
4.2 | First-line nonsurgical treatment
Current treatment strategies schedule chemotherapy as first-line adju-
vant treatment at least for the younger patients to avoid or defer
radiotherapy,2,5,6,8,10,15 reflected in a share of 64% receiving first-line
vincristine/carboplatin chemotherapy in our cohort, whereas 36% had
first-line radiotherapy. Besides being younger, the chemotherapy
cohort comprised patients with disseminated tumors, representing
36% of those <1 year at diagnosis with LGG of the optic pathways.
This corroborates previous data of a cohort of disseminated LGG; 24/
28 patients with nonsurgical treatment received first-line chemother-
apy, eight of these being infants.39
PFS following front-line radiotherapy was 80% at 5 years in our
cohort confirming results of previous series with 70% to 85% 5-years
PFS.12,13,21,40 PFS did not differ between the radiation modalities, but
was lower for patients with ganglioglioma or disseminated disease.
The extent of prior resection did not impact upon the risk of progres-
sion or death in our cohort. Larger tumor size trended with a higher
progression rate in the ACNS0221-study. Both tumor size and non-
pilocytic histology were associated with compromised survival, yet
only 49/85 patients had radiation as first-line treatment.13
First-line chemotherapy is associated with a higher initial progres-
sion rate resulting in 5-years PFS between 34% and 60% for various
regimens2,5,6,8,10,15 and was 53% for vincristine/carboplatin (+/−
etoposide) in our cohort. As previously reported, progression was
more frequent among patients with dissemination and very young
patients, especially if treatment started early after diagnosis or within
the first year of life.1,2,6,15,39,41 Although smaller postsurgical residues
prior to the start of chemotherapy proved favorable for PFS, surgery-
associated morbidity should preclude the attempt of radical resection
in critical regions.36,42,43
Mortality for the entire cohort was increased for patients
experiencing progression during or early after first chemotherapy. This
expands the result from the European randomized chemotherapy trial,
identifying progression at Week 24 as most important risk factor for
death.15 This aspect has not been detailed by de Haas et al although
their OS was in the same range as for our subgroup.16
4.3 | Salvage chemotherapy
Our data confirm the feasibility to apply consecutive lines of chemo-
therapy to further postpone radiation, as has been demonstrated by
others.16,17 Yet, PFS following second-, third- or fourth-line treatment
dropped to less than half compared to first-line—irrespective of the
choice of the successive chemotherapy regimens. Of note, PFS
remained in a comparable range for later treatment lines independent
from the modality of the prior treatment (chemo- or radiotherapy).
This contrasts sharply with the results from Scheinemann et al, where
progression rates were comparable for first- and second-line chemo-
therapy (5-years PFS-2 was 37% ± 8%) and did not reveal changes
upon further progressions either.17 In addition, their patient cohort
was younger both at diagnosis and progression and their relapsed
cohort only comprised 4/38 patients with NF1. Thus, Scheinemann's
cohort was enriched for subgroups for which our results predicted an
inferior outcome. Though, in the report of de Haas et al, PFS following
salvage chemotherapy showed a decline similar to our results in 44
patients with relapse following Baby Brain protocol of the French
Society of Pediatric Oncology (BBSFOP) first-line treatment.5,16
The decline of PFS between first and subsequent treatment lines
was not seen in our patient groups with tumor dissemination or
age < 1 year at diagnosis, specifically for infants starting their initial
treatment within the first year of life. For them, PFS following first-
line treatment was very low already and did not drop further. This cor-
responds to the results of Laithier et al and de Haas et al.16,17 For the
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subgroup of 26 infants, PFS was 34% at 3 years following first-line
chemotherapy5 corresponding to the PFS in the report of de Haas
et al.16 The relapsed BBSFOP cohort included 17/44 infants at diag-
nosis and half of the patients were still younger than 5 years at first
relapse.16
In our cohort, lower PFS was only seen in infants with OPG,
whereas infants with tumors in other regions of the brain (cerebellum,
cerebral hemispheres, mesencephalon) had an outcome equivalent to
older children and their tumors did not develop dissemination. This
aspect was not detailed in the literature so far.
Of note, PFS following third-line chemotherapy was better if
radiotherapy had been part of the prior sequence of treatments, spe-
cifically in the non-NF1 cohort. We do not know whether reactions to
the radiation interfered with the interpretation of tumor response vs
growth on MRI and prompted premature initiation of the next rescue
chemotherapy44; however, the disparate distribution of risk factors
precludes direct comparison. Although more than half of the patients
in the “chemotherapy-only” group were infants and/or had dissemi-
nated tumors, the group with prior chemo- and radiotherapy included
no infants and only three patients with dissemination, and thus, com-
prised less patients with high risk for progression.
The type and sequence of the most commonly used chemother-
apy regimens2,6,9,10,15,27,45 reached comparable PFS in the salvage
settings for our patients with just one exception. Although vinblastine
monotherapy achieved a satisfactory PFS for patients with NF1-asso-
ciated tumors, this was not the case for patients with sporadic LGG.
This effect had been observed in a small number of relapsed patients
and following primary treatment, as well.8,9 For non-NF1 patients,
PFS after second-line treatment was noticeably inferior for vinblastine
monotherapy as compared to all platinum-based combination regi-
mens in the multivariate analysis. This result is in contrast to the
report of Scheinemann et al.17 The majority of their relapsed patients
had been pretreated with carboplatin with or without vincristine (32/
38) and received vinblastine as salvage therapy (23/38).
4.4 | Salvage radiotherapy
During the observation time of up to 25 years from diagnosis, just 64
patients of the chemotherapy-first group received radiotherapy,
resulting in “radiotherapy-free” survival of 81% at 5 years and 71% at
10 years corresponding to previous reports5,8,10 (Table S7). Due to
the decreasing number of patients throughout time, our analysis can-
not answer the potential role of early radiotherapy for patients at risk
for multiple progressions following chemotherapy.
A higher risk for earlier progression following first and further
lines of chemotherapy raised debate about an earlier positioning of
radiotherapy to prevent the detrimental effect of progressive dis-
ease.46,47 Modern photon and proton therapy reduce the radiation
dose to developing brain tissue, diminishing toxicities without
compromising disease control. Still, cognitive, endocrine and clinical
late effects have been reported for highly conformal therapies but
not in older children and after reduced doses to organs at
risk.13,18,40 Currently, limitation of its use in young children is
recommended.13,22,48
Contrasting the report of Mueller et al21 with an equivalent out-
come for patients with PA following radiotherapy as first-line or sal-
vage treatment, our data stress a decline for 5-years PFS from 80.1%
for first-line radiotherapy to 48.7% after second- and 51.3% for third-
line and successive lines, as well. This pattern has been described pre-
viously23 and appears comparable, though on a higher level, to the
decline of PFS after salvage chemotherapy.
Just recently, Acharya et al recommended early radiation for a
high-risk group defined as patients with diffuse astrocytoma and/or
midbrain/thalamic tumors, since delayed radiotherapy after at least
one line of chemotherapy was associated with a significant decrement
in OS in their cohort.47 Yet, their series did not comprise disseminated
and spinal LGG and very young patients and is thus not comparable to
our cohort. Of note, a higher risk for progression was retained in the
chemotherapy-pretreated patients with disseminated tumors and
after early start of first treatment. We would argue that the decline of
PFS after salvage therapy mirrors the selection of more aggressive
tumors needing multiple treatment-lines for disease control, for
chemo- and radiotherapy alike.
4.5 | Response to salvage treatment and biology
We would not interpret the shorter PFS time after salvage therapy
(irrespective of the type of previous treatment) as tumor resistance in
the wake of pretreatment. The pattern rather corresponds to more
aggressive tumor types not identifiable by conventional histologic
criteria, up to now.38,49-53 Disseminated PAs of the optic pathways in
infants constitute the largest portion of this high-risk group with (fre-
quent) early progression and impaired OS. Unfortunately, no tissue for
molecular analysis had been secured from our patients. Risk stratifica-
tion of pediatric LGG by molecular findings could associate clinical
features like age, sex, tumor site, extent of resection and histology
with distinct molecular patterns and survival parameters in a large ret-
rospectively collected cohort,50 but patients did not follow a defined
treatment algorithm. Similarly, progression to high-grade histology,
which occurred predominantly, but not exclusively, in diffuse glioma
WHO-grade II,33 may be anticipated in the presence of specific
molecular genetic changes.50,54
4.6 | Neurofibromatosis type 1
Patients with NF1-associated LGG constituted 15% of the entire
patient group, comparable to other reports1,2,5,8; their median age at
diagnosis was almost 3 years below the non-NF1 cohort. More than
half of NF1-associated tumors (60%) were progressive or received
adjuvant treatment early after diagnosis, resulting in 5-years EFS of
35%. This apparently opposes the 5-years EFS of 57% for non-NF1
patients. Yet, in line with previous findings,55 the majority of NF1-
associated tumors were located in regions hardly amenable for
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therapeutic surgery (77% in the optic pathways, 9% in other SML
structures, 6% in the caudal brainstem) increasing the need for non-
surgical interventions.
If only OPG are considered, patients with NF1-associated tumors
received treatment less often (63%) as compared to those with spo-
radic OPG (81%), possibly reflecting a less aggressive growth behav-
ior. Since NF1 patients are not systematically registered in Germany,
we also assume a registration bias for NF1-associated OPG. In addi-
tion, the cohort of sporadic OPG is enriched for infants with dience-
phalic syndrome and dissemination; however, these data should not
mislead to postpone the start of treatment in symptomatic patients. In
line with others,56 almost three quarters of our OPG patients started
adjuvant treatment for visual impairment. Long-term survival did not
differ with respect to NF1 status.
Corroborating previous reports, PFS following first-line vincris-
tine/carboplatin chemotherapy was noticeably higher for NF1
patients compared to non-NF1 patients.2,7,8 But as for non-NF1
patients, PFS dropped to half after further lines of rescue chemother-
apy for NF1-associated tumors, though the absolute level remained
higher and no specific risk factors were obvious. Salvage radiotherapy
was used exceptionally only, but was less effective in extensive
tumors.
Molecular genetic data point to specific mutations in addition to
the underlying NF1-gene mutation which may herald an unfavorable
course of disease.57 Since the quest for molecular data to identify
patients at risk for multiple progressions requires submission of ade-
quate tumor tissue, even NF1-associated OPG may need biopsy in
the future.
4.7 | Limitations of our study
Our analysis has a pertinent shortcoming: The initial SIOP-LGG 2004
study focused upon first-line chemotherapy within the randomized
trial and not upon multiple lines of treatment or the comparison of
late effects of chemo- vs radiotherapy. The study collected only lim-
ited data on salvage therapies with respect to response assessment
and toxicity, clinical sequelae and late effects, and neuropsychological
development.
We also lack molecular-neuropathological data for most patients,
though they have been reported for the subgroup of diffuse glioma
WHO-grade II.33
A comparison of the efficacy of the three major radiation tech-
niques is beyond the scope of this report; the choice of the treatment
option was determined by individual tumor and patient characteristics
and accessibility.
5 | CONCLUSION
The majority of pediatric LGG patients can be successfully managed
within the current European treatment recommendations including
first- and further-line options. Results of first-line treatment
confirm previously identified risk factors like young age at diagno-
sis or start of treatment, tumor dissemination or early treatment
failure.
Patients progressing after front-line adjuvant treatment are at risk
of suffering multiple subsequent progressions, many of whom carry
up-front identified risk factors. Those base cases may contribute to
lower PFS rates with subsequent treatments. Nevertheless, a portion
of progressing tumors may stabilize spontaneously.
Customized treatment strategies including the careful consid-
eration of surgical and nonsurgical interventions have to be tailored
for tumor site, age and other epidemiologic preconditions and must
be decided in a multidisciplinary approach repeatedly during fol-
low-up. In view of the often “chronic” nature of LGG, each patient
is entitled to a thorough assessment of possible benefits vs their
long-term sequelae throughout the whole course of different
treatments.
Our results do not set priority to a certain sequence of specific
treatment options, since none proved superior in preventing another
progression. Rather, all can be aligned as portfolio of choices which
need balancing risks and benefits of each element. Although vinblas-
tine monotherapy may be the more effective regimen for NF1-associ-
ated tumors, non-NF1 patients seem to profit from platinum-based
combination regimens—at least when given second-line. A randomized
comparison has to test this assumption.
Patients without NF1, with disseminated tumors or those requir-
ing therapy early after diagnosis are at risk for multiple progressions
requiring repeated treatments. Further research including the correla-
tion of molecular-genetic and clinical data has to carve out the deter-
minants of this tumor biology. Since pediatric LGG has to be regarded
as a chronic, life-long disease for a large portion of patients, a popula-
tion-based registry covering a broad range of clinical aspects should
accompany all randomized trials, for which only a small subgroup will
be eligible.
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